ISSUE 3

Abstract:
Background: Cimetidine, a first-generation histamine H₂-receptor antagonist, has been widely used for the management of acid-related gastrointestinal disorders for several decades. Despite its long-standing clinical use and perceived safety, accumulating evidence indicates that cimetidine is associated with a broad spectrum of adverse drug reactions (ADRs) and clinically relevant drug–drug interactions.

Objective: This narrative review aims to comprehensively summarize the pharmacological basis, clinical manifestations, and mechanistic pathways underlying adverse reactions and drug–drug interactions associated with cimetidine.

Methods: A narrative synthesis of published clinical reports, case studies, pharmacokinetic analyses, and mechanistic investigations was undertaken to evaluate hepatic, renal, neurological, metabolic, immunological, and hypersensitivity-related adverse effects of cimetidine, along with its interaction potential.

Results: Cimetidine-induced toxicity is mediated through both pharmacokinetic mechanisms—primarily cytochrome P450 inhibition—and immunomodulatory effects. Rare but serious complications include autoimmune-like hepatitis, ANCA-associated acute tubulointerstitial nephritis, acute dystonic reactions, metabolic derangements such as lactic acidosis, and severe drug–drug interactions involving agents with narrow therapeutic indices. Emerging evidence challenges the traditional view of cimetidine as a benign therapy, particularly in vulnerable populations.

Conclusion: Although most cimetidine-associated adverse effects are uncommon, several can be severe or life-threatening. Increased clinical awareness, careful patient selection, and vigilant monitoring are essential to mitigate risks, especially given its continued over-the-counter availability.

Keywords: 

Cimetidine; adverse drug reactions; drug–drug interactions; cytochrome P450 inhibition; autoimmune-like hepatitis; ANCA-associated tubulointerstitial nephritis; dystonia; lactic acidosis; pharmacovigilance.

Abstract:
The rapid growth of nanonutritionals and probiotics has provided both opportunities and challenges in global health and regulatory science. While these medicines offer increased bioavailability, targeted distribution, and superior treatment outcomes, their incorporation into consumer markets is hampered by fragmented and uneven regulatory frameworks. This review critically examines international approaches to safety evaluation, labeling, and standardization, with a focus on significant markets such as the United States, the European Union, India, and the Asia-Pacific region. Comparative evaluations of regulatory adequacy scores show significant differences in nano disclosure, probiotic strain identification, CFU criteria, and health claim clearance. Safety issues such as nanoparticle toxicity, bioaccumulation, and probiotic strain diversity highlight the importance of testing techniques that go beyond traditional toxicology. Current labelling practices are inconsistent, limiting customer awareness and confidence. Harmonization initiatives by the WHO, Codex Alimentarius, ISO, and regional agencies show progress, but are insufficient to address transnational trade and public health threats. Future trends, such as AI-driven predictive toxicology, modified probiotics, and sustainable nanotechnology, provide both potential and regulatory challenges. The study shows that stronger international collaboration, consistent safety measures, and transparent labelling are required to combine innovation with consumer protection and progress toward a unified worldwide regulatory framework for nano-nutraceuticals and probiotics. 

Keywords: 

Nano nutraceuticals, Probiotics, Regulatory gaps, Safety assessment, Global standards, Pharmaceutical regulation, Nanotechnology, Microbiome, Harmonization, Innovation.